APP and Alzheimer disease: For instance, in a recent study examining the effects of LY2886721 in PLB-4 mice, the drug has shown improved glucose homeostasis, hepatic gluconeogenesis, insulin sensitivity and beneficial effects on APP processing, supporting the potential utilization of BACE1 inhibitors for the treatment of type 2 diabetes mellitus-associated pathologies, especially in cases when diabetes is comorbid to AD [51].